Leerink Upgrades Replimune to Outperform, Sees High Odds of FDA Approval for Melanoma Therapy

Leerink upgrades Replimune to Outperform with $17 target, citing high odds of FDA accelerated approval for RP-1 melanoma therapy after 10-3 vote.